BioSpace News Archive

Drug Development

3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH

3-V Biosciences, Inc. and Ascletis Pharma Inc. announced that 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of the FASN inhibitor TVB-2640 in patients with non-alcoholic steatohepatitis.

April 30, 2019
·
4 min read
Business

Amgen Reports First Quarter 2019 Financial Results

Amgen announced financial results for the first quarter of 2019.

April 30, 2019
·
16 min read
Deals

Tocagen to Report First Quarter 2019 Financial and Business Results on Tuesday, May 7

Tocagen Inc. announced it will report its first quarter 2019 financial results and business progress on Tuesday, May 7, 2019, after the close of the U.S. financial markets.

April 30, 2019
·
1 min read
Biotech Beach

Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting

Long-Term Data from Two Phase III Trials Show INGREZZA Sustained Improvement in Tardive Dyskinesia Symptoms in Patients Taking Concomitant Medications for Psychiatric Disorders

April 30, 2019
·
10 min read
Deals

BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update

BiondVax Pharmaceuticals Ltd. announced its fourth quarter and full year financial results for the year ended December 31, 2018 and provided a business update.

April 30, 2019
·
7 min read
Business

Zynex Announces 2019 First Quarter Earnings

Revenue increased 34% year over year to $9.2 million

April 30, 2019
·
5 min read
Business

First-quarter revenue and Cologuard test volume increased 79 percent to $162 million and 334,000, respectively

Estimated Cologuard market share increased to 4.6 percent during the first quarter

April 30, 2019
·
8 min read
Business

CryoLife Reports First Quarter 2019 Financial Results

Net loss was ($297,000), or ($0.01) per fully diluted common share; non-GAAP net income was $1.5 million, or $0.04 per fully diluted common share

April 30, 2019
·
6 min read
BioMidwest

Hill-Rom to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

Hill-Rom Holdings, Inc., announced that John Groetelaars, president and CEO, will present at the Bank of America Merrill Lynch 2019 Healthcare Conference on Tuesday, May 14, 2019, at 11:20 a.m. Pacific Time in Las Vegas.

April 30, 2019
·
1 min read
Deals

Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2019 on May 7, 2019

Array BioPharma Inc. will report financial results for the third quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, May 7, 2019 at 9:00 am ET.

April 30, 2019
·
1 min read